Evidence map›Paper›PMID 32092138›Full record

ArticleBlood advances2020

Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield.

Nosha Farhadfar, Jack W Hsu, Brent R Logan, Jennifer A Sees, Pintip Chitphakdithai, Michele W Sugrue, Hisham Abdel-Azim, Paolo N Anderlini, Christopher Bredeson, Saurabh Chhabra and 23 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 5 countries.

Nosha FarhadfarDivision of Hematology and Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, FL.
Jack W HsuDivision of Hematology and Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, FL.
Brent R LoganCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, and.
Jennifer A SeesCIBMTR, National Marrow Donor Program/Be The Match, Minneapolis, MN.
Pintip ChitphakdithaiCIBMTR, National Marrow Donor Program/Be The Match, Minneapolis, MN.
Michele W SugrueDivision of Hematology and Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, FL.
Hisham Abdel-AzimChildren's Hospital of Los Angeles, Los Angeles, CA.
Paolo N AnderliniDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.
Christopher BredesonOttawa Hospital Blood and Marrow Transplant Program and Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Saurabh ChhabraDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Miguel Angel DiazDepartment of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
Siddhartha GangulyDivision of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS.
Peiman HemattiDivision of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI.
Rammurti T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX.
Kimberly A KasowPediatric Hematology Oncology Program, University of North Carolina, Chapel Hill, NC.
Hillard M LazarusSeidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH.
Debra Kelly LynchDivision of Hematology and Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, FL.
Hemant S MurthyDivision of Hematology and Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, FL.
Richard F OlssonDivision of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Mona PapariITxM Clinical Services Cord Blood Laboratory, Rosemont, IL.
Donna PrzepiorkaCenter for Biologic Evaluation and Research, US Food and Drug Administration, North Potomac, MD.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Raquel SchearsDepartment of Emergency Medicine, Mayo Medical School, Rochester, MN.
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Melhem M SolhBlood and Marrow Transplant Program, Northside Hospital, Atlanta, GA.
Thomas SpitzerMassachusetts General Hospital, Boston, MA.
Jean A YaredBlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD.
Michael A PulsipherDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, CA.
Nirali N ShahPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Galen E SwitzerDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA; and.
Dennis L ConferCIBMTR, National Marrow Donor Program/Be The Match, Minneapolis, MN.
Bronwen E ShawCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, and.
John R WingardDivision of Hematology and Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, FL.
University of Florida Health · USNational Marrow Donor Program · USChildren's Hospital of Los Angeles · USMedical College of Wisconsin · USBaylor College of Medicine · USCenter for Biologics Evaluation and Research · USDokkyo Medical University · JPHospital Infantil Universitario Niño Jesús · ESMassachusetts General Hospital · USMayo Clinic in Arizona · USNational Institutes of Health · USNorthside Hospital · USOttawa Hospital · CAThe University of Texas MD Anderson Cancer Center · USUniversity Hospitals Seidman Cancer Center · USUniversity of Kansas · USUniversity of Maryland, Baltimore · USUniversity of North Carolina at Chapel Hill · USUniversity of Pittsburgh · USUppsala University · SE

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
NCI NIH HHS U24 CA076518NHLBI NIH HHS U24 HL138660
6 · The paper itself

Abstract

There are limited data on the effect of donor body mass index (BMI) on peripheral blood stem cell (PBSC) mobilization response to granulocyte colony-stimulating factor (G-CSF), especially in unrelated donors. Obesity has been associated with persistent leukocytosis, elevated circulating progenitor cells, and enhanced stem cell mobilization. Therefore, we hypothesized that adequate collection of CD34+ cells may be achieved with lower doses (per kilogram of body weight) of G-CSF in donors with higher BMI compared with donors with lower BMI. Using the Center for International Blood and Marrow Transplant Research database, we evaluated the impact of donor BMI on G-CSF-mobilized PBSC yield in healthy unrelated donors. We examined 20 884 PBSC donations collected at National Marrow Donor Program centers between 2006 and 2016. We found significantly higher collection yields in obese and severely obese donors compared with normal and overweight donors. An increase in average daily G-CSF dose was associated with an increase in stem cell yield in donors with normal or overweight BMI. In contrast, an increase in average daily G-CSF dose beyond 780 μg per day in obese and 900 μg per day in severely obese donors did not increase cell yield. Pain and toxicities were assessed at baseline, during G-CSF administration, and postcollection. Obesity was associated with higher levels of self-reported donation-related pain and toxicities in the pericollection and early postdonation recovery periods. This study suggests a maximum effective G-CSF dose for PBSC mobilization in obese and severely obese donors, beyond which higher doses of G-CSF add no increased yield.

Indexed as

Granulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationBody Mass IndexBody WeightHumansUnrelated DonorsGranulocyte Colony-Stimulating Factor

Identifiers

PMID32092138
PMCPMC7042992
OpenAlexW2908861200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.